Thousands of women diagnosed with breast cancer could avoid unnecessary chemotherapy thanks to a breakthrough genetic test developed to identify which patients genuinely need the treatment.
A major UK-led clinical trial has found that approximately 68% of eligible breast cancer patients could safely avoid chemotherapy, potentially sparing thousands of women its debilitating side effects.
The findings, from the OPTIMA trial led by University College London (UCL), represent an encouraging advance in personalised breast cancer treatment.
How Does the New Breast Cancer Genetic Test Work?
The test, known as Prosigna, examines the activity of 50 genes within a breast cancer tumour to help doctors predict the risk of the disease returning.
It is particularly relevant to women diagnosed with hormone receptor-positive, HER2-negative breast cancer, one of the most common forms of the disease.
By examining the tumour’s genetic characteristics, doctors can better identify patients who are unlikely to benefit significantly from chemotherapy and may be treated effectively with hormone therapy alone.
OPTIMA Trial: Thousands Could Avoid Chemotherapy
The OPTIMA trial involved 4,429 patients and compared conventional breast cancer treatment with treatment guided by the Prosigna test.
Among patients with low genomic risk scores, the five-year results showed:
- 94.8% of patients receiving chemotherapy and hormone therapy were alive without invasive breast cancer recurrence.
- 93.6% of patients receiving hormone therapy alone were alive without invasive breast cancer recurrence.
Researchers concluded that many patients could safely avoid chemotherapy without a clinically meaningful reduction in treatment effectiveness.
The findings suggest that more than 5,000 NHS patients annually could potentially avoid chemotherapy.
Read more in the official UCL report on the OPTIMA breast cancer trial.
Why Is This Such Good News for Breast Cancer Patients?
Although chemotherapy can be lifesaving, its side effects can be severe, including exhaustion, nausea, hair loss, infections and sometimes lasting nerve or heart problems.
For women who would gain little additional benefit from chemotherapy, avoiding these side effects could significantly improve their quality of life.
The Prosigna test is already available to certain NHS patients, but the OPTIMA findings could support its wider use.
Researchers have also estimated that broader testing could save the NHS approximately £4 million annually.
Early Breast Cancer Diagnosis Remains Vital
While this research offers considerable hope, early breast cancer diagnosis remains one of the most important factors in achieving successful treatment outcomes.
Unfortunately, delays can occur when suspicious symptoms are not properly investigated, mammograms are misinterpreted or patients are not referred promptly for specialist assessment.
In some cases, an avoidable delay can allow cancer to progress, potentially requiring more extensive treatment or affecting a patient’s prognosis.
Where a delay results from substandard medical care and causes avoidable harm, there may be grounds for a clinical negligence claim.
At Hutcheon Law, our specialist solicitors investigate cases involving missed diagnoses, delayed referrals and failures to investigate suspected breast cancer.
Find out more about delayed breast cancer diagnosis compensation claims and how we may be able to help.
A Welcome Breakthrough in Breast Cancer Treatment
The OPTIMA findings demonstrate how advances in medical research can improve cancer care, allowing doctors to provide more personalised treatment while avoiding unnecessary side effects.
For thousands of women facing a breast cancer diagnosis, this is particularly encouraging news.
However, access to effective treatment begins with timely investigation and accurate diagnosis. Where avoidable medical mistakes cause harm, patients deserve answers and appropriate support.
If you believe your breast cancer diagnosis was unnecessarily delayed, contact Hutcheon Law for a confidential discussion about your circumstances.
Contact Us Now To Claim
